Actavis predicts 15-20 percent export growth this year

Actavis, the manufacturer of generic drugs headquartered in Iceland, is estimating a 15-20 percent growth in exports this year. It owns a plant in Romania after acquiring local manufacturer of oncology drugs Sindan in 2006.

The company exports to all over the European Union, the US, Japan, Australia and South Africa. Last year it posted a turnover of EUR 107 million turnover, with EUR 28 million representing exports.

For this year, Actavis is looking to launch 13 new products in the OTC and cardio-vascular areas, as well as to consolidate its Decubal line of dermato-cosmetics, for which it is planning a re-launch. The production of three oncology drugs Actavis currently manufactures in Romania has been transferred to a second plant the group owns in Italy.

The production of the drugs in Romania is still ongoing, but the Italian site offers the extra capacity option. say representatives.

Read more about

Romanian startup Dwellii launches premium turnkey modular homes, with one day assembly

read more